Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05391022 Completed - Solid Tumor Clinical Trials

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

Start date: July 20, 2021
Phase: Phase 1
Study type: Interventional

Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies

NCT ID: NCT04831996 Completed - Clinical trials for Advanced Malignancies

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

Start date: May 4, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal renal function and participants with renal impairment.

NCT ID: NCT04831944 Completed - Clinical trials for Advanced Malignancies

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

Start date: March 29, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.

NCT ID: NCT04537715 Completed - Solid Tumor Clinical Trials

Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Start date: April 23, 2020
Phase: Phase 1
Study type: Interventional

The participants of this study will have advanced malignancies (also known as advanced cancer). The main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the tazemtostat (the study drug) when administered in combination with another drug. Part 1 of the study will evaluate the interaction between the drugs tazemetostat and itraconazole. Part 2 of the study will evaluate the interaction between the drugs tazemetostat and rifampin For both Parts 1 and 2, safety and the level that effects of the study drug can be tolerated (known as tolerability) will be assessed throughout.

NCT ID: NCT04353830 Completed - Clinical trials for Advanced Malignancies

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Start date: May 22, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI939 in subjects with advanced malignancies

NCT ID: NCT04328831 Completed - Clinical trials for Advanced Malignancies

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

Start date: July 31, 2020
Phase: Phase 1
Study type: Interventional

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

NCT ID: NCT04025957 Completed - Clinical trials for Advanced Malignancies

A Study of SHR-1501 in Patients With Advanced Tumors

Start date: October 30, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in patients with advanced malignancies .

NCT ID: NCT03995472 Completed - Clinical trials for Advanced Malignancies

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Start date: February 14, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.

NCT ID: NCT03907969 Completed - Clinical trials for Advanced Malignancies

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

Start date: October 9, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with advanced malignancies.

NCT ID: NCT03763149 Completed - Clinical trials for Advanced Malignancies

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

Start date: February 19, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.